STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna reported in August that adding their mRNA cancer vaccine intismeran autogene to an existing treatment slowed the return and spread of melanoma in a late-stage trial, with the source noting the drug stopped melanoma's return.
- Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the field had been waiting 'with bated breath' for the results, calling the mRNA approach 'ripe for further drug development.'
- The Parker Institute for Cancer Immunotherapy, founded by tech entrepreneur Sean Parker, framed the results as validation of an mRNA cancer strategy first devised decades ago to train the immune system to attack tumors.
- With melanoma answered, the field's open questions are which other cancers the mRNA approach can target and whether mRNA is up to the task beyond a single indication.
- Intismeran autogene is positioned as a combination therapy layered on top of an existing cancer treatment rather than a standalone vaccine.
Why it matters: Merck and Moderna's late-stage melanoma win revives momentum for mRNA cancer vaccines, making upcoming trials in other cancer types the decisive test of whether the platform can expand beyond melanoma into a broadly deployable immunotherapy approach.
Ask SkimNews
